会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PROCESS FOR PREPARING ALKYNE INTERMEDIATES FOR DENDRITIC POLYMERS
    • 制备聚合物烯烃中间体的方法
    • WO2008013618A1
    • 2008-01-31
    • PCT/US2007/014404
    • 2007-06-20
    • DENDRITIC NANOTECHNOLOGIES, INC.TOMALIA, Donald, A.SWANSON, Douglas, R.
    • TOMALIA, Donald, A.SWANSON, Douglas, R.
    • A01N57/00A61K31/66
    • C07D295/205C07D249/04
    • This invention provides a process for preparing alkyne intermediates used for making dendritic polymers. This process concerns alkyne compounds, useful as "clickable intermediates" to produce novel core reagents, branch cell reagents, surface group reagents, dendron reagents, oligomeric extender reagents, dendrimer core reagents, or dendrimer shell reagents suitable for preparing dendritic polymers, which comprises: 1) reacting acetylenic halides ( i.e. chlorides, bromides or iodides) or acetylenic mesylates/tosylates with 2-alkyl/aryl-2-oxazolines or oxazines to produce N-acetylenic-2-oxazolinium or 2-oxazinium cation salts; and 2) reacting N-acetylenic-2-oxazolinium or 2-oxazinium cation salts as catalytic reagents for the polymerization of 2-alkyl/aryl-2-oxazolines or 2-alkyl/aryl-2-oxazines; or 3) reacting propargyl tosylate or propargyl halides with 2-ethyl-2-oxazoline and then polymerizing to alkyne substituted poly(2-ethyl-2-oxazolines) with a degree of polymerization ( i.e. , dp=1-100); or 4) reacting propargyl tosylate with 2-ethyl-2-oxazoline (1:1) in the presence of sodium bromide or sodium iodide in acetonitrile to form N-propargyl-2-oxazolinium bromides/iodides, respectively; or 5) reacting 3-butyne-1,4-ditosylate in the presence of sodium iodide or sodium bromide in acetonitrile to form 3-butyne-1,4-dioxazolinium iodide or bromide, respectively.
    • 本发明提供了制备用于制备树枝状聚合物的炔烃中间体的方法。 该方法涉及可用作“可点击中间体”的炔基化合物,用于制备适用于制备树枝状聚合物的新型核心试剂,支链细胞试剂,表面试剂,树枝状试剂,低聚延伸剂试剂,树枝状聚合物核试剂或树枝状大分子壳试剂,其包括: 1)使炔基卤化物(即氯化物,溴化物或碘化物)或炔丙基甲磺酸酯/甲苯磺酸酯与2-烷基/芳基-2-恶唑啉或恶嗪反应,生成N-炔属-2-恶唑啉鎓或2-恶嗪鎓阳离子盐; 和2)N-炔属-2-恶唑啉鎓或2-恶嗪鎓阳离子盐作为用于2-烷基/芳基-2-恶唑啉或2-烷基/芳基-2-恶嗪的聚合的催化剂; 或3)使炔丙基甲苯磺酸酯或炔丙基卤化物与2-乙基-2-恶唑啉反应,然后聚合成具有聚合度(即dp = 1-100)的炔取代的聚(2-乙基-2-恶唑啉); 或4)在溴化钠或碘化钠存在下,在乙腈存在下,使甲磺酸炔丙酯与2-乙基-2-恶唑啉(1:1)反应,分别形成N-炔丙基-2-恶唑啉溴化物/碘化物; 或5)在碘化钠或溴化钠存在下在乙腈中的3-丁炔-1,4-二硫酸酯反应,分别形成3-丁炔-1,4-二氧杂环丁烷碘化物或溴化物。
    • 7. 发明申请
    • JANUS DENDRIMERS AND DENDRONS
    • JANUS DENDRIMERS和DENDRONS
    • WO2006105043A2
    • 2006-10-05
    • PCT/US2006/011160
    • 2006-03-27
    • DENDRITIC NANOTECHNOLOGIES, INC.TOMALIA, Donald, A.PULGAM, Veera, ReddySWANSON, Douglas, R.HUANG, Baohua
    • TOMALIA, Donald, A.PULGAM, Veera, ReddySWANSON, Douglas, R.HUANG, Baohua
    • A61K48/00
    • C08G83/003C08G81/00
    • This invention provides a cost effective process and new Janus dendrimers where at least two dendrons are attached at the core (with or without a connector group) and where at least two of the dendrons have different functionality. Preferred are those Janus dendrimers where at least one dendron is a PEHAM dendron. Thus these Janus dendrimers are heterobifunctional in character and use unique ligation chemistry with single site functional dendrons, di-dendrons and multi-dendrons. Also included are Janus dendrons which maybe used as intermediates to make the Janus dendrimers or to further react with another reactive moiety. These Janus dendrimers can provide several new dendrimer moieties, namely: combinatorial libraries of bifunctional structures; combined target director and signaling dendrimers; specific targeting entities for diagnostic and therapeutic applications, such as for example targeted MRI agents, targeted radionuclide delivery for diseases such as cancer, and targeted photosensitive or radiowave sensitive agents.
    • 本发明提供了一种成本有效的方法和新的Janus树枝状大分子,其中至少两个树突状结构连接在核心处(具有或不具有连接基团),并且其中至少两个树枝状突起具有不同的功能。 那些Janus树枝状大分子是首选的,其中至少有一个树突是PEHAM树突。 因此,这些Janus树枝状大分子是异性双功能的,并且使用独特的连接化学物质,其具有单位点功能性树突,二枝状突起和多枝状突起。 还包括Janus dendron,其可以用作中间体来制备Janus树枝状大分子或进一步与另一反应性部分反应。 这些Janus树枝状大分子可以提供几个新的树枝状大分子部分,即:双功能结构的组合文库; 组合目标主任和信号树枝状大分子; 用于诊断和治疗应用的特异性靶向实体,例如靶向MRI剂,用于诸如癌症的疾病的靶向放射性核素递送,以及靶向感光或无线电波敏感剂。